All In Biotech

Drug Trial Radar · NCT06442280

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution: A Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

544

Planned (sponsor's estimate)

Start

Jun 2024

Primary completion

Jan 31, 2026

Study completion Mar 30, 2026

Sponsor

Lead sponsor
University of PalermoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.

Conditions

  • Heart Failure Acute
  • Diabetes Type 2
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Preserved Ejection Fraction

Interventions

  • Dapagliflozin tabletDrug

    Dapagliflozin 10 mg 1 tablet once daily

  • Hypertonic Saline Solution, 1 MlDrug

    Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily

  • Furosemide InjectionDrug

    Furosemide 20 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diuresis from the baseline and up to 1 weekTime frame: an average of 1 week
  2. Natriuresis from the baseline and up to 1 weekTime frame: an average of 1 week
  3. Length of hospital stayTime frame: immediately after the intervention

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.